Jenscare Scientific Co., Ltd. has announced the release of the 30-day clinical follow-up results for large annulus patients in the global multicenter clinical trial of the LuX-Valve Plus transcatheter tricuspid valve replacement, known as the TRINITY study. These results were presented at the New York Valves 2025 conference in the United States. The TRINITY study is a global prospective, multicenter, single-arm clinical trial. Key safety results include a cardiovascular mortality rate of 1.3% for the full analysis set, with specific rates of 0.9% for the large annulus patients group and 2.8% for the small annulus patients group. Other clinical events such as myocardial infarction and new onset renal failure were not observed. Shareholders and potential investors are advised to exercise caution, as there is no assurance of the successful development, marketing, or commercialization of the LuX-Valve Plus.